BOLT - Company ID 0001641281
The table below shows Bolt Biotherapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.70M | $7.69M | $7.88M | $5.73M | $1.26M | $231.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $28.53M | $57.47M | $61.54M | $73.12M | $75.66M | $40.36M |
| SG&A |
Bolt Biotherapeutics, Inc. reported annual revenue of $7.70M for fiscal year 2025. That is up 0.1% from $7.69M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $231.00K (FY 2020) to $7.70M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $13.79M |
| $18.46M |
| $22.53M |
| $22.93M |
| $18.39M |
| $9.06M |
| Operating income | -$36.11M | -$73.05M | -$76.20M | -$90.32M | -$92.79M | -$49.18M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$33.38M | -$63.12M | -$69.20M | -$88.10M | -$98.59M | -$60.73M |
| EPS (diluted) | -$17.85 | -$33.06 | -$1.83 | -$2.36 | -$2.97 | - |